Hemostatic matrix products (gelatin–thrombin combinations) were first introduced in the late 1990s and received regulatory approval in the United States in 1999. Since then, they have been approved by multiple global health authorities, including the European Medicines Agency (EMA), for use as topical hemostatic agents in surgery.

These products have become widely used across surgical specialities and are now considered an essential tool for controlling bleeding during procedures.

Hemostatic Matrix.NMP is used to:

• Control bleeding during surgery when standard techniques (suturing, cauterisation, compression) are insufficient.
  

• Manage capillary, venous, and small arterial bleeding.
  

• Support hemostasis in deep, irregular, or hard-to-reach surgical sites.
  

• Assist in trauma surgeries where rapid bleeding control is needed.
  

• Provide effective bleeding control in cardiac, orthopaedic, neuro, urologic, and general surgeries.

It is used only by surgeons or trained medical personnel during operative procedures.

Hemostatic Matrix.NMP stops bleeding using two coordinated mechanisms:

1. Mechanical Action (Gelatin Granules)

• The gelatin matrix swells upon contact with blood.
  

• This creates a physical barrier over the bleeding site.
  

• It applies gentle pressure to promote clot formation.
  

2. Biochemical Action (Thrombin)

• Thrombin converts fibrinogen to fibrin, the main component of blood clots.
  

• This accelerates the natural clotting cascade.
  

• A stable clot forms quickly, sometimes within 1–2 minutes.
  

Together, these actions help achieve rapid, reliable hemostasis even in challenging surgical environments.

• Hemostatic Matrix.NMP is applied topically, directly to the bleeding site.
  

• It must be used only in a surgical setting by trained medical professionals.
  

• The surgeon determines the amount needed based on:
  

  • Size and location of bleeding
    

  • Severity of bleeding
    

  • Surgical field
    

• The matrix may be gently pressed onto the tissue for 1–2 minutes to support clot formation.
  

• Excess material should be removed after hemostasis is achieved.
  

• It must never be injected intravascularly.
  

There is no oral, IV, or intramuscular dose; it is strictly a local/topical agent.

Like all medical products, Floseal Injection may cause side effects, although not everyone experiences them.

Serious Side Effects:

• Severe allergic reactions (swelling, rash, difficulty breathing)
  

• Foreign body reactions
  

• Granuloma formation
  

• Impaired wound healing
  

• Postoperative infection at the surgical site
  

Common Side Effects:

• Mild swelling at the site of application
  

• Local irritation
  

• Temporary inflammation
  

• Minor tissue reaction due to gelatin components

Seek medical attention immediately if severe allergic or unusual postoperative symptoms occur.

• Do not inject Hemostatic Matrix into blood, as this can lead to life-threatening embolisation.
  

• Should not be used in patients with known allergy to gelatin, thrombin, or bovine-derived products.
  

• Not recommended for use in infected or contaminated wounds unless specifically cleared by the surgeon.
  

• Excessive application may delay wound healing.
  

• Use with caution in patients with:
  

  • Bleeding disorders
    

  • Autoimmune conditions
    

  • Known coagulation abnormalities
    

• Avoid use in neurosurgical procedures involving the spinal canal unless the surgeon deems it safe.

Seek urgent care if the patient develops fever, severe pain, or unusual wound discharge after surgery.

• Inform your surgical team about all medications, allergies, and medical conditions before the procedure.
  

• Follow all postoperative instructions carefully to prevent infection or wound complications.
  

• Hemostatic Matrix is not absorbed systemically, but small remnants may persist temporarily at the surgical site.
  

• Patients with a history of gelatin or thrombin sensitivity must alert their doctor.
  

• The product should be stored according to the manufacturer's guidelines to maintain sterility.
  

• Use during pregnancy or breastfeeding is considered safe only when essential and under specialist supervision.
  

• Always use the product within the sterile field to avoid contamination.

• Floseal must be applied only by a surgeon or trained medical professional.
  

• It should not be injected into blood vessels, as it may cause embolisation.
  

• Do not use in areas of active infection unless cleared by the surgeon.
  

• Inform your surgical team about all medical conditions, medications, or past allergic reactions.
  

Follow all postoperative instructions provided by your healthcare team for safe recovery.

1. Spotnitz, W. (2010). Fibrin Sealant and Hemostatic Agents in Surgical Practice. Journal of the American College of Surgeons https://journals.lww.com/journalacs/pages/default.aspx
   

2. European Medicines Agency (EMA). Hemostatic Agents Overview https://www.ema.europa.eu/en/medicines

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.